Cantor Fitzgerald analyst Josh Schimmer reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight.
Cantor Fitzgerald Reiterates Overweight on 4D Molecular Therapeutics
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.